

WEST Search History

DATE: Thursday, November 06, 2003

Set Name Query
side by side

Hit Count Set Name
result set

*DB=USPT,PGPB,JPAB,EPAB,DWPI; THES=ASSIGNEE; PLUR=YES;
OP=ADJ*

L1 histidine phosphatase or histidine protein phosphatase or
phosphohistidine hydrolase

18 L1

END OF SEARCH HISTORY

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 18 of 18 returned.****1. Document ID: US 20030092155 A1**

L1: Entry 1 of 18

File: PGPB

May 15, 2003

PGPUB-DOCUMENT-NUMBER: 20030092155

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030092155 A1

TITLE: Modified phytases

PUBLICATION-DATE: May 15, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kostrewa, Dirk	Freiburg		DE	
Pasamontes, Luis	Trimbach		CH	
Tomschy, Andrea	Grenzach-Wyhlen		DE	
Loon, Adolphus van	Rheinfelden		CH	
Vogel, Kurt	Basle		CH	
Wyss, Markus	Liestal		CH	

US-CL-CURRENT: 435/195; 424/94.6, 435/188, 435/196

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	Draw
Draw	Desc	Image									

2. Document ID: US 20020119462 A1

L1: Entry 2 of 18

File: PGPB

Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119462

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020119462 A1

TITLE: Molecular toxicology modeling

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mendrick, Donna L.	Mount Airy	MD	US	
Porter, Mark W.	Germantown	MD	US	
Johnson, Kory R.	Bethesda	MD	US	
Castle, Arthur L.	Washington	DC	US	
Elashoff, Michael R.	Germantown	MD	US	

US-CL-CURRENT: 435/6; 702/20

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWC
Draw Desc	Image										

3. Document ID: US 6630583 B1

L1: Entry 3 of 18

File: USPT

Oct 7, 2003

US-PAT-NO: 6630583

DOCUMENT-IDENTIFIER: US 6630583 B1

TITLE: Antibiotics and methods of using the same

DATE-ISSUED: October 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Novak; Rodger	New York	NY		
Tuomanen; Elaine I.	Germantown	TN		

US-CL-CURRENT: 536/23.7; 530/300, 530/324, 530/325, 530/326, 530/327, 530/328, 530/329, 530/350, 536/23.1

ABSTRACT:

The present invention discloses novel antibiotic peptides, including naturally occurring peptides. The present invention also includes the nucleic acid sequences encoding such peptides and the corresponding amino acid sequences. Methods of identifying, making, and using the antibiotic peptides are also disclosed. The present invention further provides novel proteins involved in the regulation of bacterial autolysis.

5 Claims, 27 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	RWC
Draw Desc	Image									

4. Document ID: US 6599735 B1

L1: Entry 4 of 18

File: USPT

Jul 29, 2003

US-PAT-NO: 6599735

DOCUMENT-IDENTIFIER: US 6599735 B1

TITLE: Continuous fermentation system

DATE-ISSUED: July 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bartok; Attila	Zurich			CH
Mueh; Thorsten	Leverkusen			DE
Rueckel; Markus	Penzberg			DE

US-CL-CURRENT: 435/286.5; 435/289.1, 435/299.2, 435/810

ABSTRACT:

A fermentation assembly comprising: (a) a vessel for culturing living cells; (b) at least two storage flasks in fluid communication with the vessel for supply of liquids and a first transport means for transferring the liquids from the storage flasks to the vessel; (c) individual appliances operably connected to the transport means for monitoring the supply of the contents of the storage flasks to the vessel; (d) a harvest flask in fluid communication with the vessel and a second transport means for transferring the fermentation broth from the vessel to the harvest flask; and (e) a device operably connected to the first transport means for controlling and maintaining a constant dilution rate in the vessel with varying rates of individual supply of liquid from the storage flasks to the vessel is disclosed.

6 Claims, 100 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 93

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Draw
Desc	Image									

5. Document ID: US 6391605 B1

L1: Entry 5 of 18

File: USPT

May 21, 2002

US-PAT-NO: 6391605

DOCUMENT-IDENTIFIER: US 6391605 B1

**** See image for Certificate of Correction ****

TITLE: Modified phytases

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kostrewa; Dirk	Freiburg			DE
Pasamontes; Luis	Trimbach			CH
Tomschy; Andrea	Grenzach-Wyhlen			DE
van Loon; Adolphus	Rheinfelden			CH
Vogel; Kurt	Basel			CH
Wyss; Markus	Liestal			CH

US-CL-CURRENT: 435/196; 424/94.6

ABSTRACT:

A process for the production of a modified phytase with a desired property improved over the property of the corresponding unmodified phytase is disclosed, as well as modified phytases, polynucleotides encoding modified phytases, and animal feed including modified phytases.

24 Claims, 97 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 95

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Draw
Desc	Image									

6. Document ID: US 6331407 B1

L1: Entry 6 of 18

File: USPT

Dec 18, 2001

US-PAT-NO: 6331407

DOCUMENT-IDENTIFIER: US 6331407 B1

TITLE: Antibiotics and methods of using the same

DATE-ISSUED: December 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Novak, Rodger	Memphis	TN		
Tuomanen, Elaine I.	Germantown	TN		

US-CL-CURRENT: 435/7.34; 435/243, 435/252.1, 435/253.4, 435/7.2, 435/7.32, 514/12

ABSTRACT:

The present invention discloses novel antibiotic peptides, including naturally occurring peptides. The present invention also includes the nucleic acid sequences encoding such peptides and the corresponding amino acid sequences. Methods of identifying, making, and using the antibiotic peptides are also disclosed. The present invention further provides novel proteins involved in the regulation of bacterial autolysis.

8 Claims, 26 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Draw
Draw Desc	Image									

7. Document ID: US 6245502 B1

L1: Entry 7 of 18

File: USPT

Jun 12, 2001

US-PAT-NO: 6245502

DOCUMENT-IDENTIFIER: US 6245502 B1

**** See image for Certificate of Correction ****

TITLE: Target system

DATE-ISSUED: June 12, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Emi, Bernhard	Zollikofen			CH

US-CL-CURRENT: 435/4; 435/194

ABSTRACT:

The bacterial phosphotransferase system (PTS) as a drug target system catalyses the uptake and phosphorylation of carbohydrates. It is further involved in signal transduction, e.g. catabolite repression, chemotaxis, and allosteric regulation of metabolic enzymes and transporters. It is ubiquitous in bacteria but does not occur in eukaryotes. This uniqueness and the pleiotropic function make the PTS a target for the development of new antimicrobials. Assays are described that lead to the discovery of

compounds which uncouple the PTS, by acting as protein histidine/cysteine phosphatases. Uncoupling of the PTS leads to inhibition of carbohydrate transport, repression of catabolite controlled genes (e.g. certain virulence genes) and depletion of phosphoenolpyruvate. Compounds from combinatorial libraries with high affinity for phosphoenolpyruvate-protein-phosphatase (Enzyme 1) serve as lead structures for the development of inhibitors and uncouplers of the PTS.

8 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMW
Draw Desc	Image									

8. Document ID: US 5763490 A

L1: Entry 8 of 18

File: USPT

Jun 9, 1998

US-PAT-NO: 5763490
DOCUMENT-IDENTIFIER: US 5763490 A

TITLE: Treating prostate cancer with tartrate ions

DATE-ISSUED: June 9, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lebioda; Lukasz	Columbia	SC		
Jakob; Clarissa G.	Columbia	SC		

US-CL-CURRENT: 514/574; 435/199

ABSTRACT:

A method is disclosed for treating prostate cancer in males by administration of tartrate ions from a tartrate derivative. The tartrate ions in the bloodstream bind to and inhibit prostatic acid phosphatase.

5 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PMW
Draw Desc	Image									

9. Document ID: WO 3006493 A2

L1: Entry 9 of 18

File: EPAB

Jan 23, 2003

PUB-NO: WO003006493A2
DOCUMENT-IDENTIFIER: WO 3006493 A2
TITLE: HISTIDINE PHOSPHATASE INTERACTING PROTEIN WITH 180KD

PUBN-DATE: January 23, 2003

INVENTOR-INFORMATION:

NAME	COUNTRY
KELLNER, RONALD	DE
HOCK, BJOERN	DE

INT-CL (IPC): C07 K 14/00
EUR-CL (EPC): C07K014/47

ABSTRACT:

CHG DATE=20030403 STATUS=N>PHPIP-180 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-180 polypeptides and polynucleotides in diagnostic assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	FullC
Draw Desc	Image									

10. Document ID: WO 2074796 A2

L1: Entry 10 of 18

File: EPAB

Sep 26, 2002

PUB-NO: WO002074796A2
DOCUMENT-IDENTIFIER: WO 2074796 A2
TITLE: HISTIDINE PHOSPHATASE INTERACTING PROTEIN WITH 240KD

PUBN-DATE: September 26, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
HOCK, BJOERN	DE
DUECKER, KLAUS	DE
KELLNER, ROLAND	DE

INT-CL (IPC): C07 K 14/00
EUR-CL (EPC): C07K014/47

ABSTRACT:

CHG DATE=20021101 STATUS=O>PHPIP-240 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-240 polypeptides and polynucleotides in diagnostic assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	FullC
Draw Desc	Image									

11. Document ID: WO 2070676 A2

L1: Entry 11 of 18

File: EPAB

Sep 12, 2002

PUB-NO: WO002070676A2
DOCUMENT-IDENTIFIER: WO 2070676 A2
TITLE: USE OF PROTEIN HISTIDINE PHOSPHATASE

PUBN-DATE: September 12, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
KELLNER, ROLAND	DE
KLUMPP, SUSANNE	DE

INT-CL (IPC): C12 N 9/00
EUR-CL (EPC): C12N009/88; C12N009/16

ABSTRACT:

CHG DATE=20021002 STATUS=O>The invention relates to the use of polypeptides with protein histidine phosphatase activity derived from mammals, antibodies directed against them and DNA or RNA sequences complementary to mRNA sequences encoding polypeptides with protein histidine phosphatase activity for the modulation of ATP-citrate lyase and treatment of correlated pathophysiologic functions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PubC
Draw Desc	Image									

12. Document ID: WO 2066507 A2

L1: Entry 12 of 18

File: EPAB

Aug 29, 2002

PUB-NO: WO002066507A2
DOCUMENT-IDENTIFIER: WO 2066507 A2
TITLE: HISTIDINE PHOSPHATASE INTERACTING PROTEIN WITH 120KD

PUBN-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
HOCK, BJOERN	DE
DUECKER, KLAUS	DE
KELLNER, ROLAND	DE

INT-CL (IPC): C07 K 14/47; C12 N 15/12; C12 N 1/21; C07 K 16/46; C07 K 16/18; G01 N 33/68
EUR-CL (EPC): C07K014/47

ABSTRACT:

CHG DATE=20021002 STATUS=O>PHPIP-120 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. also disclosed are methods for utilizing PHPIP-120 polypeptides and polynucleotides in diagnostic assays.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	PubC
Draw Desc	Image									

13. Document ID: WO 2003006499 A2

L1: Entry 13 of 18

File: DWPI

Jan 23, 2003

DERWENT-ACC-NO: 2003-221716
DERWENT-WEEK: 200321

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New TPR1 polypeptide, useful in diagnostic assays and for identifying agonist or antagonist compounds of the TPR1 polypeptide, which are potentially useful in therapy

INVENTOR: HENTSCH, B; HOCK, B

PRIORITY-DATA: 2001EP-0116641 (July 13, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 2003006499 A2	January 23, 2003	E	043	C07K014/47

INT-CL (IPC): C07 K 14/47

ABSTRACTED-PUB-NO: WO2003006499A

BASIC-ABSTRACT:

NOVELTY - A new TPR1 polypeptide comprising:

- (a) a sequence encoded by a polynucleotide comprising the sequence having 2757 bp given in the specification;
- (b) a sequence comprising 726-amino acid sequence given in the specification;
- (c) a sequence having at least 95% identity with (B); or
- (d) fragments or variants of (A)-(C).

The TPR1 ligand of (A)-(D) has the ability to bind specifically to Protein Histidine Phosphatase Interacting Partner receptor.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) a polynucleotide;
- (2) an expression system comprising the polynucleotide capable of producing the polypeptide when the expression vector is present in a compatible host cell;
- (3) a recombinant host cell comprising the vector or its membrane expressing the polypeptide;
- (4) a process for producing the polypeptide;
- (5) a fusion protein comprising the immunoglobulin Fc-region and the polypeptide;
- (6) an antibody immunospecific for the polypeptide; and
- (7) a method for screening to identify compounds that stimulate or inhibit the function or level of the polypeptide.

USE - The polypeptide is useful in diagnostic assays and for identifying agonist or antagonist compounds of the polypeptide TPR1 (claimed), which are potentially useful in therapy.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

Print

14. Document ID: WO 2003006493 A2

L1: Entry 14 of 18

File: DWPI

Jan 23, 2003

DERWENT-ACC-NO: 2003-210420

DERWENT-WEEK: 200320

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New Protein Histidine Phosphatase Interacting Partner of 180KD (PHPIP-180), useful in diagnostic assays and for identifying agonist or antagonist compounds of the PHPIP-180 polypeptide, which are potentially useful in therapy

INVENTOR: HOCK, B; KELLNER, R

PRIORITY-DATA: 2001EP-0116640 (July 13, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 2003006493 A2	January 23, 2003	E	047	C07K014/00

INT-CL (IPC): C07 K 14/00

ABSTRACTED-PUB-NO: WO2003006493A

BASIC-ABSTRACT:

NOVELTY - A Protein Histidine Phosphatase Interacting Partner of 180KD (PHPIP-180) polypeptide comprising a 571 residue amino acid sequence (S1), encoded by a 3312 base pair sequence (S2), both given in the specification, having at least 95 % identity with (S1), or comprising fragments of them, is new. The PHPIP-180 ligand of (A)-(D) has the ability to bind specifically to Survivin or its variant.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a polynucleotide encoding the novel polypeptide;
- (2) an expression vector comprising the polynucleotide of (1) capable of producing the polypeptide when the expression vector is present in a compatible host cell;
- (3) a recombinant host cell comprising the vector of (2) or its membrane expressing the novel polypeptide;
- (4) a process for producing the novel polypeptide;
- (5) a fusion protein comprising the immunoglobulin Fc-region and the novel polypeptide;
- (6) an antibody immunospecific for the novel polypeptide; and
- (7) a method for screening to identify compounds that stimulate or inhibit the function or level of the novel polypeptide.

USE - The polypeptide is useful in diagnostic assays and for identifying agonist or antagonist compounds of the polypeptide PHPIP-180 (claimed), which are potentially useful in therapy.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

PMOC

15. Document ID: WO 200274796 A2

L1: Entry 15 of 18

File: DWPI

Sep 26, 2002

DERWENT-ACC-NO: 2002-759879

DERWENT-WEEK: 200282

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New human Protein Histidine Phosphatase Interacting Partner of 240kD polypeptides and polynucleotides, useful for diagnosing or treating diseases e.g. schizophrenia

INVENTOR: DUECKER, K; HOCK, B ; KELLNER, R

PRIORITY-DATA: 2001EP-0103780 (February 16, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200274796 A2	September 26, 2002	E	039	C07K014/00

INT-CL (IPC): C07 K 14/00

ABSTRACTED-PUB-NO: WO 200274796A

BASIC-ABSTRACT:

NOVELTY - Protein Histidine Phosphatase Interacting Partner of 240kD (PHPIP-240) ligand polypeptide (P1) comprising:

(a) a polypeptide comprising 1684-amino acid sequence and encoded by a polynucleotide having 7500 bp sequence; or

(b) a polypeptide having at least 95% identity with (a); or

(c) a fragment or variant of (a) or (b), is new.

DETAILED DESCRIPTION - (P1) has the ability to bind specifically to the PHP1 receptor having an amino acid sequence or its variant not given in the specification.

INDEPENDENT CLAIMS are also included for:

(1) a polynucleotide comprising:

(a) a sequence having at least 95% identity with the and encoding (P1);

(b) a sequence having at least 100 nucleotides or its fragment having at least 15 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having the 7500 bp sequence;

(c) a RNA equivalent of (1.1) or (1.2); or

(d) a variant, fragment or complement of (1.1)-(1.3);

(2) an expression system comprising a polynucleotide capable of producing (P1), when the expression vector is present in a compatible host cell;

(3) a recombinant host cell comprising the expression vector, or its membrane expressing (P1);

(4) producing (P1);

(5) a fusion protein consisting of the immunoglobulin Fc-region and (P1);

(6) an antibody immunospecific for (P1); or

(7) screening compounds that stimulate or inhibit the function or level of (P1).

ACTIVITY - Cytostatic; Neuroleptic; Antianemic.

No suitable data given.

MECHANISM OF ACTION - Vaccine; PHPIP-240-Antagonist; PHPIP-240-Agonist.

USE - The PHPIP-240 ligand polypeptides and polynucleotides are useful for diagnosing or treating diseases or disorders e.g. schizophrenia, congenital dyserythropoietic anemia type III or sarcoma, or as vaccines.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

PMW

16. Document ID: WO 200270676 A2

L1: Entry 16 of 18

File: DWPI

Sep 12, 2002

DERWENT-ACC-NO: 2002-723261
DERWENT-WEEK: 200278
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Polypeptides with Protein Histidine Phosphatase activity useful for modulating ATP-citrate-lyase activity, particularly for treating e.g. hyperlipidemia, cardiovascular diseases or tumors, or for promoting fat loss

INVENTOR: KELLNER, R; KLUMPP, S

PRIORITY-DATA: 2001EP-0105774 (March 8, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200270676 A2	September 12, 2002	E	022	C12N009/00

INT-CL (IPC): C12 N 9/00

ABSTRACTED-PUB-NO: WO 200270676A
BASIC-ABSTRACT:

NOVELTY - A polypeptide with the biological activity of a Protein Histidine Phosphatase (PHP), which has a high specificity for phosphohistidine or a homologue variant, useful for modulating ATP-citrate-lyase (EC 4.1.3.8) activity, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) an antibody, or its fragment, directed to the polypeptide with PHP activity, useful for modulating ATP-citrate-lyase activity; and

(2) a DNA sequence, which is complementary to the mRNA sequence of PHP, with at least one of the following sequences comprising 374, 48, 99 or 132 bp fully defined in the specification.

ACTIVITY - Antilipemic; Cardiovascular; Anorectic; Anti-inflammatory; Cytostatic; Neuroprotective.

No biological data given.

MECHANISM OF ACTION - ATP-citrate-lyase modulator.

USE - The polypeptide with PHP activity, the antibody, and the DNA are useful for modulating ATP-citrate-lyase activity, or for the manufacture a medicament for treating pathophysiologic conditions susceptible to the modulation of ATP-citrate-lyase activity (e.g. hyperlipidemia, hypercholesterolemia, cardiovascular diseases, obesity, inflammatory diseases, tumors, diseases of the nervous system or hypocitraturia). These are also useful for the manufacture of a medicament for controlling weight, promoting fat loss and for appetite suppression (all claimed). These diseases also include Alzheimer's disease, senile dementia, scrapie, osteoarthritis, psoriasis, multiple sclerosis, dermatitis, Raynaud's syndrome, or Crohn's disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Draw	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	-------

17. Document ID: WO 200266507 A2

L1: Entry 17 of 18

File: DWPI

Aug 29, 2002

DERWENT-ACC-NO: 2002-674915
DERWENT-WEEK: 200272
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: New Protein Histidine Phosphatase Interacting Partner of 120kD ligand polypeptides, useful for diagnosing or treating diseases e.g. autism, anemia or malignant fibrous histiocytomas

INVENTOR: DUECKER, K; HOCK, B ; KELLNER, R

PRIORITY-DATA: 2001EP-0103779 (February 16, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 200266507 A2	August 29, 2002	E	041	C07K014/47

INT-CL (IPC): C07 K 14/47; C07 K 16/18; C07 K 16/46; C12 N 1/21; C12 N 15/12; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200266507A
BASIC-ABSTRACT:

NOVELTY - An isolated Protein Histidine Phosphatase Interacting Partner of 120kD (PHPIP-120) ligand polypeptide comprising:

- (a) a polypeptide consisting of a sequence (P1) having 1047 amino acids and encoded by a polynucleotide comprising a sequence (N1) having 3732 bp;
- (b) a polypeptide comprising a sequence having at least 95% identity to (a); or
- (c) fragment and variant of (a) or (b), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) a polynucleotide comprising:
 - (i) a sequence having at least 95% identity to (N1) and encoding a polypeptide sequence having at least 95% identity to (P1);
 - (ii) a sequence having at least 100 nucleotides obtained by screening a library under stringent hybridization conditions with a labeled probe having (N1) or its fragment having at least 15 nucleotides; or
 - (iii) variant, fragment or complement of (i) or (ii);
- (2) an expression system comprising the polynucleotide capable of producing the polypeptide, where the expression vector is present in a compatible host cell;
- (3) a recombinant host cell comprising the expression vector or its membrane expressing the polypeptide;
- (4) a process for producing the polypeptide;
- (5) a fusion protein consisting of the Immunoglobulin Fc-region and the polypeptide;
- (6) an antibody immunospecific for the polypeptide; or
- (7) a method for screening compounds that stimulate or inhibit the function or level of the polypeptide.

ACTIVITY - Cytostatic; Nootropic; Antianemic.

No biological data given.

MECHANISM OF ACTION - PHPIP-120-Agonist; PHPIP-120-Antagonist; Gene therapy.

USE - The polynucleotide is useful for chromosome localization studies or for tissue expression studies. The polypeptide is useful for treating diseases e.g. autism, anemia

or malignant fibrous histiocytomas. The polynucleotide and polypeptide are also useful in diagnostic assays or as vaccines against the mentioned diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

18. Document ID: MX 2001008941 A1 WO 200052175 A1 AU 200038080 A NO 200104261 A EP 1159430 A1 BR 200008607 A CZ 200103172 A3 KR 2002002400 A CN 1342205 A SK 200101224 A3 HU 200200241 A2 JP 2002537814 W ZA 200108129 A AU 762809 B

L1: Entry 18 of 18

File: DWPI

Jul 1, 2003

DERWENT-ACC-NO: 2000-572187

DERWENT-WEEK: 200366

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Histidine phosphatase, useful for diagnosis and treatment of cancers, immune disorders, viral infection, genetic disorders, and heart disease

INVENTOR: KELLNER, R; KLUMPP, S

PRIORITY-DATA: 1999DE-1009388 (March 4, 1999)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
MX 2001008941 A1	July 1, 2003		000	A61K038/46
WO 200052175 A1	September 8, 2000	E	039	C12N015/55
AU 200038080 A	September 21, 2000		000	
NO 200104261 A	September 3, 2001		000	C12N000/00
EP 1159430 A1	December 5, 2001	E	000	C12N015/55
BR 200008607 A	January 2, 2002		000	C12N015/55
CZ 200103172 A3	December 12, 2001		000	C12N015/55
KR 2002002400 A	January 9, 2002		000	C07K014/435
CN 1342205 A	March 27, 2002		000	C12N015/55
SK 200101224 A3	June 4, 2002		000	C12N015/55
HU 200200241 A2	May 28, 2002		000	C12N015/55
JP 2002537814 W	November 12, 2002		041	C12N015/09
ZA 200108129 A	March 26, 2003		049	C12N000/00
AU 762809 B	July 3, 2003		000	C12N015/55

INT-CL (IPC): A61 K 38/46; A61 P 3/00; A61 P 9/00; A61 P 25/00; A61 P 35/00; A61 P 43/00; C07 K 14/435; C07 K 16/40; C12 N 0/00; C12 N 9/16; C12 N 15/09; C12 N 15/55

ABSTRACTED-PUB-NO: WO 200052175A

BASIC-ABSTRACT:

NOVELTY - A polypeptide (I) with the biological activity of a histidine phosphatase which has a high specificity for phosphohistidine and a molecular weight of 13000-15000, obtainable by purification from mammalian tissue by at least one anion exchange chromatography, one gel filtration and one affinity chromatography step, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a polypeptide (II) with the biological activity of a histidine phosphatase which has a high specificity for phosphohistidine and a molecular weight of 13000-15000, comprising the amino acid sequence:

(M)AVADLALIPDVDIDSDGVFKYVLIRVHSAPRSGAPAAESKEIVRGYKWAHEYHADIYDKVSGDMQKQG CDC-

ECLGGGRISHQSQDKKIHVYGYSMAYGPAQHAISTEKIKAKYPDYEVTWANDGY;

(2) a polypeptide (III) with the biological activity of a histidine phosphatase which has a high specificity for phosphohistidine and a molecular weight of 13000-15000, the amino acid sequence of which has a homology of 64-99% compared with the sequence DCECLGGGRISHQSQDX1KIHVYGYSM- X2YGX3AQH;

(3) a DNA (IV) coding for (I), (II) or (III);

(4) pharmaceutical preparation comprising (I), (II) or (III), where appropriate, together with suitable excipients, carriers and other active ingredients; and

(5) an antibody directed to (I), (II) or (III).

X1 = K or R;

X2 = A or G; and

X3 = P or R.

ACTIVITY - Cytostatic; immunomodulatory; virucide; cardiant.

No biological data is given.

MECHANISM OF ACTION - None given.

USE - The histidine phosphatase can be used for diagnosis and treatment of pathological states of cell regulation and cell growth. These include cancers, immune disorders, viral infection, genetic disorders, and heart disease. The histidine phosphatase can also be used for identifying agonists and antagonists which can be used to treat conditions associated with N-phosphorylation imbalance.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Draw	Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	------	------	-------

Generate Collection

Print

Terms	Documents
histidine phosphatase or histidine protein phosphatase or phosphohistidine hydrolase	18

Display Format: -

Change Format

[Previous Page](#)

[Next Page](#)